Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter



How to prescribe 

JULUCA (dolutegravir/rilpivirine) – a complete once-daily, single-pill regimen, taken with a meal1

JULUCA is for patients who want to reduce their ARV exposure and:

Juluca patients

JULUCA is indicated for the treatment of HIV-1 infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/ml) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any NNRTI or INI.1


The safety and efficacy of Juluca in pregnancy have not yet been established. Limited data are available regarding the use of dolutegravir during pregnancy. Lower exposures of dolutegravir or rilpivirine were observed when taken once daily, in combination with a background regimen, during pregnancy. In phase 3 studies, lower rilpivirine exposure, similar to that seen during pregnancy, has been associated with an increased risk of virological failure. No recommendations for dose adjustments can be made for Juluca. Therefore, use of Juluca during pregnancy is not recommended1

Drug-Drug Interactions

  • No known interactions with contraceptives, statins, PDE-5 inhibitors1 
  • Contraindicated:1 
    • Proton pump inhibitors
    • Dofetilide
    • Rifampicin, rifapentine
    • Carbamazepine, oxcarbazepine, phenobarbital, phenytoin
    • Systemic dexamethasone
    • St John's wort
  • Particular caution with:1 
    • Antacids and H2-antagonists (dose separation, use once-daily H2RAs only)
    • Multivitamins or calcium/iron supplements (dose separation if cannot take with a meal at same time as JULUCA)
  • Dose adjustment of metformin may be required1